论文部分内容阅读
目的观察2型糖尿病患者应用磷酸西格列汀后血清Apelin水平的变化及磷酸西格列汀对2型糖尿病患者的治疗作用。方法 46例糖尿病患者随机分为A组(二甲双胍组)及B组(二甲双胍联合西格列汀组),采用放免法检测血清Apelin水平,空腹及餐后血糖、糖化血红蛋白,空腹胰岛素,以稳态模型方法计算胰岛素抵抗指数(HOMA-IR),计算体重指数(BMI),观察低血糖及胃肠道不适反应。结果 AB两组治疗前Apelin水平相比较差异无统计学意义[(277.3±48.4)ng/L vs.(279.8±55.3)ng/L,P>0.05];B组治疗后Apelin水平低于A组治疗后Apelin水平[(231.9±50.6)ng/L vs.(244.0±46.2)ng/L,P<0.05]。B组治疗后空腹血糖低于A组治疗后空腹血糖[(6.64±1.63)mmol/L vs.(7.09±1.58)mmol/L,P<0.05]。B组治疗后餐后血糖低于A组治疗后餐后血糖[(9.05±2.91)mmol/L vs.(9.32±3.01)mmol/L,P<0.05]。B组治疗后糖化血红蛋白低于A组治疗后糖化血红蛋白[(6.8±0.6)%vs.(7.2±0.7)%,P<0.05]。B组治疗后空腹胰岛素低于A组治疗后空腹胰岛素[(12.36±4.18)mU/L vs.(13.29±4.71)mU/L,P<0.05]。B组治疗后体重指数与A组治疗后体重指数相比较差异无统计学意义[(26.95±3.30)kg/m2 vs.(26.98±3.44)kg/m2,P>0.05]。结论应用西格列汀可以降低2型糖尿病患者的Apelin水平。
Objective To investigate the changes of serum Apelin level in patients with type 2 diabetes mellitus after receiving sitagliptin phosphate and the therapeutic effect of sitagliptin on type 2 diabetes mellitus. Methods Forty-six diabetic patients were randomly divided into two groups: metformin group (group A) and metformin group (metformin combined with sitagliptin group). Apelin levels, fasting and postprandial blood glucose, glycosylated hemoglobin and fasting insulin were measured by radioimmunoassay. The model method was used to calculate the insulin resistance index (HOMA-IR), calculate the body mass index (BMI), observe the hypoglycemia and gastrointestinal discomfort reaction. Results There was no significant difference in Apelin levels between the two groups before treatment (277.3 ± 48.4 ng / L vs. 279.8 ± 55.3 ng / L, P> 0.05). The Apelin level in group B was lower than that in group A The level of Apelin after treatment [(231.9 ± 50.6) ng / L vs. (244.0 ± 46.2) ng / L, P <0.05]. Fasting plasma glucose in group B was lower than that in group A [(6.64 ± 1.63) mmol / L vs. (7.09 ± 1.58) mmol / L, P <0.05]. The postprandial blood glucose of group B was lower than that of group A after treatment ([9.05 ± 2.91] mmol / L vs. (9.32 ± 3.01) mmol / L, P <0.05]. The levels of HbA1c in group B after treatment were lower than those in group A [(6.8 ± 0.6)% vs (7.2 ± 0.7)%, P <0.05]. Fasting insulin in group B was lower than fasting insulin in group A after treatment [(12.36 ± 4.18) mU / L vs. (13.29 ± 4.71) mU / L, P <0.05]. There was no significant difference in body mass index between group B after treatment and body mass index after treatment [(26.95 ± 3.30) kg / m2 vs (26.98 ± 3.44) kg / m2, P> 0.05]. Conclusion Sitagliptin can reduce Apelin levels in type 2 diabetic patients.